Free Access
Med Sci (Paris)
Volume 26, Number 8-9, Août-Septembre 2010
Page(s) 734 - 739
Section M/S revues
Published online 15 August 2010
  1. Urban JD, Clarke WP, von Zastrow M, et al. Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 2007 ; 320 : 1-13. [Google Scholar]
  2. Audet N, Paquin-Gobeil M, Landry-Paquet O, et al. Internalization and Src activity regulate the time course of ERK activation by delta opioid receptor ligands. J Biol Chem 2005 ; 280 : 7808-16. [Google Scholar]
  3. Kenakin T. Functional selectivity through protean and biased agonism: who steers the ship? Mol Pharmacol 2007 ; 72 : 1393-401. [Google Scholar]
  4. May LT, Hill SJ. ERK phosphorylation: spatial and temporal regulation by G protein-coupled receptors. Int J Biochem Cell Biol 2008 ; 40 : 2013-7. [Google Scholar]
  5. Mathews JL, Smrcka AV, Bidlack JM. A novel G-betagamma-subunit inhibitor selectively modulates mu-opioid-dependent antinociception and attenuates acute morphine-induced antinociceptive tolerance and dependence. J Neurosci 2008 ; 28 : 12183-9. [Google Scholar]
  6. McDowell TS. Fentanyl decreases Ca2+ currents in a population of capsaicin-responsive sensory neurons. Anesthesiology 2003 ; 98 : 223-31. [Google Scholar]
  7. Marker CL, Lujan R, Loh HH, Wickman K. Spinal G-protein-gated potassium channels contribute in a dose-dependent manner to the analgesic effect of mu- and delta- but not kappa-opioids. J Neurosci 2005 ; 25 : 3551-9. [Google Scholar]
  8. Zheng H, Loh HH, Law Py. Beta-arrestin-dependent mu-opioid receptor-activated extracellular signal-regulated kinases (ERK) Translocate to Nucleus in Contrast to G protein-dependent ERK activation. Mol Pharmacol 2008 ; 73 : 178-90. [Google Scholar]
  9. Kieffer BL, Gaveriaux-Ruff C. Exploring the opioid system by gene knockout. Prog Neurobiol 2002 ; 66 : 285-306. [Google Scholar]
  10. Negus SS, Schrode K, Stevenson GW. Micro/kappa opioid interactions in rhesus monkeys: implications for analgesia and abuse liability. Exp Clin Psychopharmacol 2008 ; 16 : 386-99. [Google Scholar]
  11. Beaudry H, Proteau-Gagné A, Li S, et al. Differential noxious and motor tolerance of chronic delta opioid receptor agonists in rodents. Neuroscience 2009 ; 161 : 381-91. [Google Scholar]
  12. Walsh SL, Strain EC, Abreu ME, Bigelow GE. Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans. Psychopharmacology (Berl) 2001 ; 157 : 151-62. [Google Scholar]
  13. McLaughlin JP, Myers LC, Zarek PE, et al. Prolonged kappa opioid receptor phosphorylation mediated by G-protein receptor kinase underlies sustained analgesic tolerance. J Biol Chem 2004 ; 279 : 1810-8. [Google Scholar]
  14. Bruchas MR, Land BB, Aita M, et al. Stress-induced p38 mitogen-activated protein kinase activation mediates kappa-opioid-dependent dysphoria. J Neurosci 2007 ; 27 : 11614-23. [Google Scholar]
  15. May CN, Dashwood MR, Whitehead CJ, Mathias CJ. Differential cardiovascular and respiratory responses to central administration of selective opioid agonists in conscious rabbits: correlation with receptor distribution. Br J Pharmacol 1989 ; 98 : 903-13. [Google Scholar]
  16. Porreca F, Mosberg HI, Hurst R, et al. Roles of mu, delta and kappa opioid receptors in spinal and supraspinal mediation of gastrointestinal transit effects and hot-plate analgesia in the mouse. J Pharmacol Exp Ther 1984 ; 230 : 341-8. [Google Scholar]
  17. Cowan A, Zhu XZ, Mosberg HI, et al. Direct dependence studies in rats with agents selective for different types of opioid receptor. J Pharmacol Exp Ther 1988 ; 246 : 950-5. [Google Scholar]
  18. Broom DC, Nitsche JF, Pintar JE, et al. Comparison of receptor mechanisms and efficacy requirements for delta-agonist-induced convulsive activity and antinociception in mice. J Pharmacol Exp Ther 2002 ; 303 : 723-9. [Google Scholar]
  19. Pradhan AA, Becker JA, Scherrer G, et al. In vivo delta opioid receptor internalization controls behavioral effects of agonists. PLoS One 2009 ; 4 : e5425. [Google Scholar]
  20. Alves ID, Ciano KA, Boguslavski V, et al. Selectivity, cooperativity, and reciprocity in the interactions between the delta-opioid receptor, its ligands, and G-proteins. J Biol Chem 2004 ; 279 : 44673-82. [Google Scholar]
  21. Audet N, Gales C, Archer-Lahlou E, et al. Bioluminescence resonance energy transfer assays reveal ligand-specific conformational changes within preformed signaling complexes containing deltaopioid receptors and heterotrimeric G proteins. J Biol Chem 2008 ; 283 : 15078-88. [Google Scholar]
  22. Allouche S, Polastron J, Hasbi A, et al. Differential G-protein activation by alkaloid and peptide opioid agonists in the human neuroblastoma cell line SK-N-BE. Biochem J 1999 ; 342 : 71-8. [Google Scholar]
  23. Stanasila L, Lim WK, Neubig RR, Pattus F. Coupling efficacy and selectivity of the human muopioid receptor expressed as receptor-Galpha fusion proteins in Escherichia coli. J Neurochem 2000 ; 75 : 1190-9. [Google Scholar]
  24. Gupta A, Decaillot FM, Devi LA. Targeting opioid receptor heterodimers: strategies for screening and drug development. AAPS J 2006 ; 8 : E153-9. [Google Scholar]
  25. Fan T, Varghese G, Nguyen T, et al. A role for the distal carboxyl tails in generating the novel pharmacology and G protein activation profile of mu and delta opioid receptor hetero-oligomers. J Biol Chem 2005 ; 280 : 38478-88. [Google Scholar]
  26. Johnson EA, Oldfield S, Braksator E, et al. Agonist-selective mechanisms of mu-opioid receptor desensitization in human embryonic kidney 293 cells. Mol Pharmacol 2006 ; 70 : 676-85. [Google Scholar]
  27. Gabra BH, Bailey CP, Kelly E, et al. Pre-treatment with a PKC or PKA inhibitor prevents the development of morphine tolerance but not physical dependence in mice. Brain Res 2008 ; 1217 : 70-7. [Google Scholar]
  28. Pineyro G. Fonctional selectivity at opioid receptors. In : Neve KA, ed. Fonctional selectivity of G protein-coupled receptor ligands. New york : Humana Press, 2009 : 243-66. [Google Scholar]
  29. Groer CE, Tidgewell K, Moyer RA, et al. An opioid agonist that does not induce micro-opioid receptor: arrestin interactions or receptor internalization. Mol Pharmacol 2007 ; 71 : 549-57. [Google Scholar]
  30. Okura T, Varga EV, Hosohata y, et al. Agonist-specific down-regulation of the human delta-opioid receptor. Eur J Pharmacol 2003 ; 459 : 9-16. [Google Scholar]
  31. Archer-Lahlou E, Audet N, Amraei MG, et al. Src promotes delta opioid receptor (DOR) desensitization by interfering with receptor recycling. J Cell Mol Med 2009 ; 13 : 147-63. [Google Scholar]
  32. Ho IK, Loh HH, Way EL. Effects of cyclic 3’, 5’-adenosine monophosphate on morphine tolerance and physical dependence. J Pharmacol Exp Ther 1973 ; 185 : 347-57. [Google Scholar]
  33. Bernstein MA, Welch SP. Effects of spinal versus supraspinal administration of cyclic nucleotide-dependent protein kinase inhibitors on morphine tolerance in mice. Drug Alcohol Depend 1997 ; 44 : 41-6. [Google Scholar]
  34. yoshimura M, Wu PH, Hoffman PL, Tabakoff B. Overexpression of type 7 adenylyl cyclase in the mouse brain enhances acute and chronic actions of morphine. Mol Pharmacol 2000 ; 58 : 1011-6. [Google Scholar]
  35. Li S, Lee ML, Bruchas MR, et al. Calmodulin-stimulated adenylyl cyclase gene deletion affects morphine responses. Mol Pharmacol 2006 ; 70 : 1742-9. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.